OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Disease pathophysiology:
PPA begins very gradually and initially is experienced as difficulty thinking of common words while speaking or writing. PPA progressively worsens to the point where verbal communication by any means is very difficult. The ability to understand what others are saying or what is being read also declines.
Disease statistics:
In a double-blind placebo controlled trial in six subjects with PNFA and showed a mild improvement in the mean length of utterances. There is one case report of PPA showing some improvement with the use of oral steroids. The improvement was mild and the patient received steroids for only three months. An open label trial of memantine for 26 weeks in FTD, SD, and PPA patients failed to show significant benefit.
Disease treatment:
There are two kinds of treatments available for individuals with the logopenic variant of PPA. First, medication treatments can be borrowed from among those available for Alzheimer’s disease. These may help slow down the decline in memory and language. Second, individuals with the logopenic variant of PPA can take advantage of behavioral and speech therapies and improve their own naming and comprehension skills.
Major research on disease:
Magnetic resonance imaging using VBM reveals atrophy in the inferior and middle frontal gyri, dorsal motor and premotor cortex, anterior insula, basal ganglia, and supplementary motor area in the left hemisphere. Episodic memory, visuospatial function, attention and executive functions are normal early in the course. Patients are usually independent and have intact social skills.